Airsickness prevention in helicopter passengers

Aviation Space and Environmental Medicine

Volumn 78, Issue 4 I, 2007, Pages 408-413

  Estrada III, Arthur ^a,b   LeDuc, Patricia A ^a   Curry, Ian P ^a   Phelps, Shean E ^a   Fuller, Daniel R ^a  

^a U S ARMY AEROMEDICAL RESEARCH LABORATORY   (United States)

^b USAARL   (United States)

Author keywords

Acustimulation; Antiemetics; Meclizine; Motion sickness; Promethazine; Scopolamine

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; CAFFEINE; MECLOZINE; PROMETHAZINE; SCOPOLAMINE;

ACUPRESSURE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FLIGHT; HELICOPTER; HUMAN; MALE; MOTION SICKNESS; NAUSEA; PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; SOLDIER; UNSPECIFIED SIDE EFFECT;

ACOUSTIC STIMULATION; ADOLESCENT; ADULT; AIRCRAFT; ANTIEMETICS; HEALTH SURVEYS; HUMANS; MALE; MECLIZINE; MILITARY MEDICINE; MILITARY PERSONNEL; MOTION SICKNESS; MUSCARINIC ANTAGONISTS; PROMETHAZINE; QUESTIONNAIRES; SCOPOLAMINE;

BUTEOGALLUS;

EID: 34247162322     PISSN: 00956562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. (DSM IV). Washington, DC: American Psychiatric Association; 1996:212.
2. Armstrong HG. Air sickness. In: Armstrong HG, ed. Aerospace medicine. Baltimore: Williams & Wilkins; 1961:219.
3. Babe KS, Serafin WE. Histamine, bradykinin, and their antagonists. In: Hardman JG, ed. Goodman & Gilman's The pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Publishing Company; 1996:581-600.
4. Bertolucci LE, DiDario B. Efficacy of a portable acustimulation device in controlling seasickness. Aviat Space Environ Med 1995; 66:1155-8.
5. Blumenthal M, Goldberg A, Brinkmann J. Herbal medicine: Expanded Commission Monographs. Newton, MA: Integrative Medicine Communications; 2000:359-66.
6. Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Hardman JG, ed. Goodman & Gilman's The pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Publishing Company; 1996:141-60.
7. Bruce DG, Golding JF, Hockenhull N, et al. Acupressure and motion sickness. Aviat Space Environ Med 1990; 61:361-5.
8. Clissold SP, Heel RC. Transdermal hyoscine (Scopolamine): A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985; 29:189-207.
9. Cummings S, Ullman D. Everybody's guide to homeopathic medicines, 3rd ed. New York: Penguin Putnam; 1997:174.
10. DeHart RL. Fundamentals of aerospace medicine, 2nd ed. Baltimore: Williams and Wilkins; 1996:385-96.
11. Dinges D, Pack F, Williams K, et al. Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4-5 hours per night. Sleep 1997; 20:267-77.
12. Dobie TG, May JG. Cognitive-behavioral management of motion sickness. Aviat Space Environ Med 1994; 65:C1-C20.
13. Drug facts and comparisons. St. Louis, MO: Facts and Comparisons®; 1999:258-9.
14. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth 2000; 84:367-71.
15. Eyeson-Annan M, Peterken C, Brown B, et al. Visual and vestibular components of motion sickness. Aviat Space Environ Med 1996; 67:955-62.
16. Fischer PR. Travel with infants and children. Infect Dis Clin N Am 1998; 12:355-68.
17. nd ed. Baltimore: Williams & Wilkins; 1996:393.
18. Gordon CR, Ben-Aryeh H, Spitzer O, et al. Seasickness susceptibility, personality factors and salivation. Aviat Space Environ Med 1994; 65:610-4.
19. Gower DW, Fowkles J. Simulator sickness in the UH-60 (Black Hawk) flight simulator. Fort Rucker, AL: U.S. Army Aeromedical Research Laboratory; USAARL Report No. 89-25; 1989: 26-7.
20. Hoffman BB, Lefkowitz RJ. Catecholamines and sympathomimetic drugs. In: Goodman AG, Rall TW, Nies AS, Taylor P, eds. Goodman & Gilman's the pharmacological basis of therapeutics. New York: Pergamon Press; 1990: 187-200.
21. Hu S, Stritzel R, Chandler A, Stern RM. P6 acupressure reduces symptoms of vection-induced motion sickness. Aviat Space Environ Med 1995; 66:631-4.
22. Johnson, DM. Introduction to and review of simulator sickness research. Fort Rucker, AL: U.S. Army Research Institute - Rotary Wing Aviation Research Unit; ARI Report No. 1832; 2005:13.
23. Kellogg RS, Kennedy RS, Graybiel A. Motion sickness symptomatology of labyrinthine defective and normal subjects during zero gravity maneuvers. Aerosp Med 1965; 36:315-8.
24. Kohl RL, Calkins DS, Mandell AJ. Arousal and stability: the effects of five new sympathomimetic drugs suggest a new principle for the prevention of space motion sickness. Aviat Space Environ Med 1986; 57:137-43.
25. Lawther A, Griffin MJ. A survey of the occurrence of motion sickness amongst passengers at sea. Aviat Space Environ Med 1988; 59:399-406.
26. Lieberman HR, Wurtman RJ, Emde GG, et al. The effects of low doses of caffeine on human performance and mood. Psychopharmacology 1987; 92:308-12.
27. Lienert GA, Huber HP. Differential effects of coffee on speed and power tests. J Psychol 1966; 63:269-74.
28. McLellan TM, Kamimori GH, Bell DG, et al. Caffeine maintains vigilance and marksmanship in simulated urban operations with sleep deprivation. Aviat Space Environ Med 2005; 76:39-45.
29. Paul MA, MacLellan M, Gray G. Motion-sickness medications for aircrew: impact on psychomotor performance. Aviat Space Environ Med 2005; 76:560-5.
30. Physicians Desk Reference. Montvale, NJ: Medical Economics Company, Inc.; 2001. 1894-6; Meclizine: 2469; Phenergan: 3419-20; Transdermal Scopolamine: 2138-40.
31. Wood CD, Stewart JJ, Wood MJ, et al. Therapeutic effects of antimotion sickness medications on the secondary symptoms of motion sickness. Aviat Space Environ Med 1990; 61:157-61.